HighVista Strategies’s Sarepta Therapeutics SRPT Stock Holding History

HighVista Strategies’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,212	Closed	-$333K	–	172
2025 Q1	$333K	Buy	+5,212	New	+$549K	0.13%	136
2024 Q3	–	Sell	-2,364	Closed	-$374K	–	165
2024 Q2	$374K	Buy	+2,364	New	+$304K	0.14%	123
2023 Q4	–	Sell	-4,781	Closed	-$580K	–	145
2023 Q3	$580K	Sell	4,781 -224	-4%	-$25.3K	0.27%	89
2023 Q2	$573K	Sell	5,005 -2,708	-35%	-$349K	0.26%	114
2023 Q1	$1.06M	Hold	7,713	–	–	0.87%	33
2022 Q4	$999K	Sell	7,713 -296	-4%	-$34.3K	0.59%	44
2022 Q3	$885K	Sell	8,009 -1,572	-16%	-$158K	0.51%	48
2022 Q2	$718K	Sell	9,581 -1,729	-15%	-$127K	0.43%	54
2022 Q1	$884K	Buy	+11,310	New	+$866K	0.56%	46
2021 Q1	–	Sell	-5,667	Closed	-$966K	–	139
2020 Q4	$966K	Buy	+5,667	New	+$840K	0.62%	29
2020 Q3	–	Sell	-2,570	Closed	-$412K	–	130
2020 Q2	$412K	Buy	+2,570	New	+$350K	0.34%	58

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HighVista Strategies's SRPT Position: Q2 2025 in Review

HighVista Strategies sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 5,212 shares — an estimated $333K sold.

HighVista Strategies first reported a position in SRPT in Q2 2020 and held it in 11 quarters. The position peaked at $1.06M in Q1 2023. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

HighVista Strategies reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
HighVista Strategies sold 5,212 Sarepta Therapeutics shares in Q2 2025, an estimated $333K.
HighVista Strategies first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 11 quarters.
HighVista Strategies's Sarepta Therapeutics position peaked at $1.06M in Q1 2023.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.